ArticleRheumatology and therapy2024

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.

Gerd R Burmester et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.